Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Frequency of the TREM2 R47H Variant in Various Neurodegenerative Disorders.

Ayer AH, Wojta K, Ramos EM, Dokuru D, Chen JA, Karydas AM, Papatriantafyllou JD, Agiomyrgiannakis D, Kamtsadeli V, Tsinia N, Sali D, Gylys KH, Agosta F, Filippi M, Small GW, Bennett DA, Gearing M, Juncos JL, Kramer J, Lee SE, Yokoyama JS, Mendez MF, Chui H, Zarow C, Ringman JM, Kilic U, Babacan-Yildiz G, Levey A, DeCarli CS, Cotman CW, Boxer AL, Miller BL, Coppola G.

Alzheimer Dis Assoc Disord. 2019 Sep 10. doi: 10.1097/WAD.0000000000000339. [Epub ahead of print]

PMID:
31513029
2.

Apolipoprotein E/Amyloid-β Complex Accumulates in Alzheimer Disease Cortical Synapses via Apolipoprotein E Receptors and Is Enhanced by APOE4.

Bilousova T, Melnik M, Miyoshi E, Gonzalez BL, Poon WW, Vinters HV, Miller CA, Corrada MM, Kawas C, Hatami A, Albay R 3rd, Glabe C, Gylys KH.

Am J Pathol. 2019 Aug;189(8):1621-1636. doi: 10.1016/j.ajpath.2019.04.010. Epub 2019 May 17.

PMID:
31108099
3.

Suppression of tau propagation using an inhibitor that targets the DK-switch of nSMase2.

Bilousova T, Elias C, Miyoshi E, Alam MP, Zhu C, Campagna J, Vadivel K, Jagodzinska B, Gylys KH, John V.

Biochem Biophys Res Commun. 2018 May 23;499(4):751-757. doi: 10.1016/j.bbrc.2018.03.209. Epub 2018 Apr 9.

4.

Neuronal pentraxin 1: A synaptic-derived plasma biomarker in Alzheimer's disease.

Ma QL, Teng E, Zuo X, Jones M, Teter B, Zhao EY, Zhu C, Bilousova T, Gylys KH, Apostolova LG, LaDu MJ, Hossain MA, Frautschy SA, Cole GM.

Neurobiol Dis. 2018 Jun;114:120-128. doi: 10.1016/j.nbd.2018.02.014. Epub 2018 Mar 6.

PMID:
29501530
5.

iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases.

Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, Yeromin AV, Scarfone VM, Marsh SE, Fimbres C, Caraway CA, Fote GM, Madany AM, Agrawal A, Kayed R, Gylys KH, Cahalan MD, Cummings BJ, Antel JP, Mortazavi A, Carson MJ, Poon WW, Blurton-Jones M.

Neuron. 2017 Apr 19;94(2):278-293.e9. doi: 10.1016/j.neuron.2017.03.042.

6.

Tau Spread, Apolipoprotein E, Inflammation, and More: Rapidly Evolving Basic Science in Alzheimer Disease.

Gonzalez B, Abud EM, Abud AM, Poon WW, Gylys KH.

Neurol Clin. 2017 May;35(2):175-190. doi: 10.1016/j.ncl.2017.01.001. Review.

7.

Pharmacological Rescue of Long-Term Potentiation in Alzheimer Diseased Synapses.

Prieto GA, Trieu BH, Dang CT, Bilousova T, Gylys KH, Berchtold NC, Lynch G, Cotman CW.

J Neurosci. 2017 Feb 1;37(5):1197-1212. doi: 10.1523/JNEUROSCI.2774-16.2016. Epub 2016 Dec 16.

9.

Altered brain energetics induces mitochondrial fission arrest in Alzheimer's Disease.

Zhang L, Trushin S, Christensen TA, Bachmeier BV, Gateno B, Schroeder A, Yao J, Itoh K, Sesaki H, Poon WW, Gylys KH, Patterson ER, Parisi JE, Diaz Brinton R, Salisbury JL, Trushina E.

Sci Rep. 2016 Jan 5;6:18725. doi: 10.1038/srep18725.

10.

Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases.

Bilousova T, Miller CA, Poon WW, Vinters HV, Corrada M, Kawas C, Hayden EY, Teplow DB, Glabe C, Albay R 3rd, Cole GM, Teng E, Gylys KH.

Am J Pathol. 2016 Jan;186(1):185-98. doi: 10.1016/j.ajpath.2015.09.018.

11.

Plasma BDNF levels associate with Pittsburgh compound B binding in the brain.

Hwang KS, Lazaris AS, Eastman JA, Teng E, Thompson PM, Gylys KH, Cole GM, Apostolova LG; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement (Amst). 2015 Jun 1;1(2):187-193.

12.

Low plasma ApoE levels are associated with smaller hippocampal size in the Alzheimer's disease neuroimaging initiative cohort.

Teng E, Chow N, Hwang KS, Thompson PM, Gylys KH, Cole GM, Jack CR Jr, Shaw LM, Trojanowski JQ, Soares HD, Weiner MW, Apostolova LG; Alzheimer’s Disease Neuroimaging Initiative.

Dement Geriatr Cogn Disord. 2015;39(3-4):154-66. doi: 10.1159/000368982. Epub 2014 Dec 24.

13.

Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.

Sokolow S, Henkins KM, Bilousova T, Gonzalez B, Vinters HV, Miller CA, Cornwell L, Poon WW, Gylys KH.

J Neurochem. 2015 May;133(3):368-79. doi: 10.1111/jnc.12991. Epub 2015 Jan 13.

14.

Conformation-dependent oligomers in cerebrospinal fluid of presymptomatic familial Alzheimer's disease mutation carriers.

Ringman JM, Tomic JL, Coppola G, Elashoff D, Gylys KH, Glabe CG.

Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):652-7. doi: 10.1159/000345771. Epub 2012 Dec 15.

15.

Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples.

Tai LM, Bilousova T, Jungbauer L, Roeske SK, Youmans KL, Yu C, Poon WW, Cornwell LB, Miller CA, Vinters HV, Van Eldik LJ, Fardo DW, Estus S, Bu G, Gylys KH, Ladu MJ.

J Biol Chem. 2013 Feb 22;288(8):5914-26. doi: 10.1074/jbc.M112.442103. Epub 2013 Jan 4.

16.

Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study.

Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL, Cole GM.

Alzheimers Res Ther. 2012 Oct 29;4(5):43. doi: 10.1186/alzrt146. eCollection 2012.

17.

Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype.

Ringman JM, Elashoff D, Geschwind DH, Welsh BT, Gylys KH, Lee C, Cummings JL, Cole GM.

Arch Neurol. 2012 Jun;69(6):757-64. doi: 10.1001/archneurol.2012.277.

18.

Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses.

Henkins KM, Sokolow S, Miller CA, Vinters HV, Poon WW, Cornwell LB, Saing T, Gylys KH.

Brain Pathol. 2012 Nov;22(6):826-33. doi: 10.1111/j.1750-3639.2012.00598.x. Epub 2012 May 23.

19.

Isolation of synaptic terminals from Alzheimer's disease cortex.

Sokolow S, Henkins KM, Williams IA, Vinters HV, Schmid I, Cole GM, Gylys KH.

Cytometry A. 2012 Mar;81(3):248-54. doi: 10.1002/cyto.a.22009. Epub 2011 Dec 28.

20.

Apolipoprotein E level and cholesterol are associated with reduced synaptic amyloid beta in Alzheimer's disease and apoE TR mouse cortex.

Arold S, Sullivan P, Bilousova T, Teng E, Miller CA, Poon WW, Vinters HV, Cornwell LB, Saing T, Cole GM, Gylys KH.

Acta Neuropathol. 2012 Jan;123(1):39-52. doi: 10.1007/s00401-011-0892-1. Epub 2011 Oct 22.

21.

Preferential accumulation of amyloid-beta in presynaptic glutamatergic terminals (VGluT1 and VGluT2) in Alzheimer's disease cortex.

Sokolow S, Luu SH, Nandy K, Miller CA, Vinters HV, Poon WW, Gylys KH.

Neurobiol Dis. 2012 Jan;45(1):381-7. doi: 10.1016/j.nbd.2011.08.027. Epub 2011 Sep 3.

22.

AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly.

Sokolow S, Henkins KM, Bilousova T, Miller CA, Vinters HV, Poon W, Cole GM, Gylys KH.

Neurobiol Aging. 2012 Aug;33(8):1545-55. doi: 10.1016/j.neurobiolaging.2011.05.011. Epub 2011 Jul 7.

23.

High levels of synaptosomal Na(+)-Ca(2+) exchangers (NCX1, NCX2, NCX3) co-localized with amyloid-beta in human cerebral cortex affected by Alzheimer's disease.

Sokolow S, Luu SH, Headley AJ, Hanson AY, Kim T, Miller CA, Vinters HV, Gylys KH.

Cell Calcium. 2011 Apr;49(4):208-16. doi: 10.1016/j.ceca.2010.12.008. Epub 2011 Mar 5.

24.

Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation.

Ringman JM, Gylys KH, Medina LD, Fox M, Kepe V, Flores DL, Apostolova LG, Barrio JR, Small G, Silverman DH, Siu E, Cederbaum S, Hecimovic S, Malnar M, Chakraverty S, Goate AM, Bird TD, Leverenz JB.

Neurosci Lett. 2011 Jan 10;487(3):287-92. doi: 10.1016/j.neulet.2010.10.039. Epub 2010 Nov 19. Erratum in: Neurosci Lett. 2011 Mar 17;491(2):163.

25.

Smoking enhances risk for new external genital warts in men.

Wiley DJ, Elashoff D, Masongsong EV, Harper DM, Gylys KH, Silverberg MJ, Cook RL, Johnson-Hill LM.

Int J Environ Res Public Health. 2009 Mar;6(3):1215-34. doi: 10.3390/ijerph6031215. Epub 2009 Mar 20.

26.

Biochemical markers in persons with preclinical familial Alzheimer disease.

Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL.

Neurology. 2008 Jul 8;71(2):85-92. doi: 10.1212/01.wnl.0000303973.71803.81. Epub 2008 May 28.

PMID:
18509095
27.

Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes.

Fein JA, Sokolow S, Miller CA, Vinters HV, Yang F, Cole GM, Gylys KH.

Am J Pathol. 2008 Jun;172(6):1683-92. doi: 10.2353/ajpath.2008.070829. Epub 2008 May 8.

28.

Smokers at higher risk for undetected antibody for oncogenic human papillomavirus type 16 infection.

Wiley DJ, Wiesmeier E, Masongsong E, Gylys KH, Koutsky LA, Ferris DG, Barr E, Yu Rao J; Proof of Principle Study Investigative Group.

Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):915-20.

29.

Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex.

Gylys KH, Fein JA, Yang F, Miller CA, Cole GM.

Neurobiol Aging. 2007 Jan;28(1):8-17. Epub 2005 Dec 5.

PMID:
16332401
30.
32.

Rapid annexin-V labeling in synaptosomes.

Gylys KH, Fein JA, Wiley DJ, Cole GM.

Neurochem Int. 2004 Feb;44(3):125-31.

PMID:
14568554
33.
34.

Caspase inhibition protects nerve terminals from in vitro degradation.

Gylys KH, Fein JA, Cole GM.

Neurochem Res. 2002 Jun;27(6):465-72.

PMID:
12199150
35.

Pharmacology department.

Gylys KH.

J Cardiovasc Nurs. 2001 Jul;15(4):91-5. Review.

PMID:
11419668
36.

Quantitative characterization of crude synaptosomal fraction (P-2) components by flow cytometry.

Gylys KH, Fein JA, Cole GM.

J Neurosci Res. 2000 Jul 15;61(2):186-92.

PMID:
10878591
37.

Pharmacology department: pharmacologic approaches to abnormal blood lipids.

Gylys KH.

J Cardiovasc Nurs. 2000 Jan;14(2):9-15. Review.

PMID:
10653272
38.

Pharmacology department. Antimicrobial resistance.

Gylys KH.

J Cardiovasc Nurs. 1999 Jan;13(2):66-9. Review.

PMID:
9888064
39.

Pharmacology.

Gylys KH.

J Cardiovasc Nurs. 1998 Apr;12(3):52-6. Review.

PMID:
9547452
40.

Selectivity of hemicholinium mustard, an affinity ligand, for the high-affinity choline transport system.

Gylys KH, Abdalah I, Jenden DJ.

Neuropharmacology. 1997 Nov-Dec;36(11-12):1741-6.

PMID:
9517446
41.

cAMP decreases steady-state levels of delta-opioid receptor mRNA in NG108-15 cells.

Gylys KH, Tran N, Magendzo K, Zaki P, Evans CJ.

Neuroreport. 1997 Jul 7;8(9-10):2369-72.

PMID:
9243642
42.

Regulation of acetylcholine synthesis in the presence of hemicholinium mustard.

Gylys KH, Jenden DJ.

Life Sci. 1996;58(22):1937-46.

PMID:
8637422
43.

Characterization of the irreversible inhibition of high-affinity choline transport produced by hemicholinium mustard.

Gylys KH, Mellin C, Amstutz R, Jenden DJ.

J Neurochem. 1992 Oct;59(4):1302-8.

PMID:
1402882

Supplemental Content

Loading ...
Support Center